Search Results - "Maroni, Bradley J"

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis by Eckardt, Kai-Uwe, Agarwal, Rajiv, Aswad, Ahmad, Awad, Ahmed, Block, Geoffrey A, Bacci, Marcelo R, Farag, Youssef M.K, Fishbane, Steven, Hubert, Harold, Jardine, Alan, Khawaja, Zeeshan, Koury, Mark J, Maroni, Bradley J, Matsushita, Kunihiro, McCullough, Peter A, Lewis, Eldrin F, Luo, Wenli, Parfrey, Patrick S, Pergola, Pablo, Sarnak, Mark J, Spinowitz, Bruce, Tumlin, James, Vargo, Dennis L, Walters, Kimberly A, Winkelmayer, Wolfgang C, Wittes, Janet, Zwiech, Rafal, Chertow, Glenn M

“…Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident…”
Get full text

Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients by Luo, Jiacong, MD, MS, MPH, Jensen, Donna E., PhD, Maroni, Bradley J., MD, Brunelli, Steven M., MD

“…Background Hemodialysis patients with erythropoiesis-stimulating agent (ESA) hyporesponsiveness have been a topic of active research. However, there have been…”
Get full text

Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS by Pifer, Trinh B., Mccullough, Keith P., Port, Friedrich K., Goodkin, David A., Maroni, Bradley J., Held, Philip J., Young, Eric W.

“…Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Nutritional status is strongly associated with outcomes among…”
Get full text

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease by Pergola, Pablo E, Spinowitz, Bruce S, Hartman, Charlotte S, Maroni, Bradley J, Haase, Volker H

“…Current treatment of anemia in chronic kidney disease (CKD) with erythropoiesis-stimulating agents can lead to substantial hemoglobin oscillations above target…”
Get more information

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients by Nissenson, Allen R., Swan, Suzanne K., Lindberg, Jill S., Soroka, Steven D., Beatey, Robert, Wang, Chao, Picarello, Nancy, McDermott-Vitak, Anna, Maroni, Bradley J.

“…Background: Darbepoetin alfa (Aranesp; Amgen, Thousand Oaks, CA) is a new erythropoiesis-stimulating protein with a threefold longer terminal half-life than…”
Get full text

Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD Study by Kopple, Joel D., Greene, Tom, Chumlea, W. Cameroon, Hollinger, Donna, Maroni, Bradley J., Merrill, Donna, Scherch, Laura K., Schulman, Gerald, Wang, Shin-Ru, Zimmer, Gail S.

“…Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD Study. The relationship between the protein-energy…”
Get full text

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease by Martin, Edouard R, Smith, Mark T, Maroni, Bradley J, Zuraw, Qing C, deGoma, Emil M

“…Therapeutic options for the treatment of anemia secondary to chronic kidney disease (CKD) remain limited. Vadadustat (AKB-6548) is an oral hypoxia-inducible…”
Get more information

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents by Haase, Volker H, Chertow, Glenn M, Block, Geoffrey A, Pergola, Pablo E, deGoma, Emil M, Khawaja, Zeeshan, Sharma, Amit, Maroni, Bradley J, McCullough, Peter A

“…ABSTRACT Background Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in…”
Get full text

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis by Allon, Michael, Kleinman, Kenneth, Walczyk, Michael, Kaupke, Charles, Messer‐Mann, Louise, Olson, Kurt, Heatherington, Anne C., Maroni, Bradley J.

“…Objective The aim of this multicenter, randomized, open‐label study was to compare the pharmacokinetic and pharmacodynamic profiles of darbepoetin alfa, a new…”
Get full text

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients by Sibbel, Scott, Maroni, Bradley J., Brunelli, Steven M.

“…Residence at higher altitude has been associated with improved anemia parameters and lower mortality rates among end-stage renal disease (ESRD) patients…”
Get full text

Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study by Gilbertson, David T, Hu, Yan, Peng, Yi, Maroni, Bradley J, Wetmore, James B

“…Given regulatory and reimbursement changes in anemia management, we examined hemoglobin variability in a contemporary cohort of maintenance hemodialysis…”
Get more information

Role of nutrition in prevention of the progression of renal disease by Maroni, B.J, Mitch, W.E

“…In rats with renal disease, low-protein diets slow the decline in renal function, histologic damage, and mortality. Low-protein (and phosphorus) diets can also…”
Get full text

Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study by Kopple, Joel D., Levey, Andrew S., Greene, Tom, Chumlea, W. Cameron, Gassman, Jennifer J., Hollinger, Donna L., Maroni, Bradley J., Merrill, Donna, Scherch, Laura K., Schulman, Gerald, Wang, Shin-Ru, Zimmer, Gail S., Modification of Diet in Renal Disease Study Group

“…Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. The safety of dietary protein and phosphorous…”
Get full text

Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease by Lerner, Gary, Kale, Arundhati S, Warady, Bradley A, Jabs, Kathy, Bunchman, Timothy E, Heatherington, Anne, Olson, Kurt, Messer-Mann, Louise, Maroni, Bradley J

“…Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in…”
Get full text

Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices by Combe, Christian, McCullough, Keith P, Asano, Yasushi, Ginsberg, Nancy, Maroni, Bradley J, Pifer, Trinh B

“…Nutritional markers are important predictors of morbidity and mortality in dialysis patients. The Clinical Practice Guidelines for Nutrition in Chronic Renal…”
Get full text

Working group session report: chronic renal and gastrointestinal disease by Senior, J R, Maroni, B J

Get more information

Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and practices by Combe, Christian, McCullough, Keith P., Asano, Yasushi, Ginsberg, Nancy, Maroni, Bradley J., Pifer, Trinh B.

“…Background: Nutritional markers are important predictors of morbidity and mortality in dialysis patients. The Clinical Practice Guidelines for Nutrition in…”
Get full text

Vancomycin redistribution: Dosing recommendations following highflux hemodialysis by Pollard, Theresa A., Lampasona, Victor, Akkerman, Shawn, Tom, Karen, Hooks, Michael A., Mullins, Richard E., Maroni, Bradley J.

“…Vancomycin redistribution: Dosing recommendations following highflux hemodialysis. Although increased vancomycin clearance has been reported with highly…”
Get full text

Na+, K+, and BP homeostasis in man during furosemide: Effects of prazosin and captopril by Wilcox, Christopher S., Guzman, Nicholas J., Mitch, William E., Kelly, Ralph A., Maroni, Bradley J., Souney, Paul F., Rayment, Carolyn M., Braun, Lyndon, Colucci, Robert, Loon, Nicholas R.

“…Na+, K+, and BP homeostasis in man during furosemide: Effects of prazosin and captopril. Furosemide increases sodium (Na+) and potassium (K+) excretion but if…”
Get full text

Should protein intake be restricted in predialysis patients? by Walser, Mackenzie, Mitch, William E., Maroni, Bradley J., Kopple, Joel D.

Get full text